 |
Arthramid® In PracticeAuthor: Contura Vet
Hosted by Dr. Jason Lowe, Chief Veterinary Officer at Contura Vet, Arthramid in Practice brings together leading veterinarians and researchers to explore the evolving landscape of joint health across equine and canine patients. From the latest evidence on osteoarthritis management to practical insights on treatment protocols and case selection, each episode is designed to inform the decisions you make in practice every day. Science-led conversation about what is working, what is changing, and what comes next in joint disease management. Language: en Genres: Health & Fitness, Medicine Contact email: Get it Feed URL: Get it iTunes ID: Get it |
Listen Now...
WEBINAR REPLAY: Dosing with Confidence: Practical Use of 2.5% iPAAG in Equine Patients
Episode 7
Wednesday, 3 June, 2026
Please Note: This is a webinar recording, if you prefer to watch with video to see the slides they reference, this can be found on our Arthramid Equine YouTube Channel. Catch the replay of the recorded CE session from May 2026 on how 2.5% iPAAG (Arthramid) is used in equine joint disease, with a focus on dosing decisions and real-world case management. Dr. Jason Lowe (Chief Veterinary Officer, Contura Vet) opens with a refresher on what 2.5% iPAAG is and how it works as a mechano-modulating synovial implant, including the research underpinning its effect on the synovial membrane. He is joined by two clinicians sharing cases from everyday practice:Dr. Sean Allison, Cleveland Equine ClinicDr. Beau Whitaker, Salado Equine Medical CenterWhat 2.5% iPAAG is and how it targets the synovium to address synovitis and fibrosisThe research behind its effect on synovial membrane elasticityFindings from a retrospective review of Dr. Allison's own caseload (around 100 horses, 138 joints)Dosing rationale based on joint size and severity of diseaseCase-based discussion across the hip, shoulder, stifle, lower hock joints, and digital flexor tendon sheathUse in low-motion joints, post-surgical cases, and repeat or top-up dosingThe discussion moves from mechanism to the questions clinicians actually face: how much to use, how often, in which joint, and how 2.5% iPAAG fits alongside existing therapies and in more complex or non-responding cases.What the session covers:
